Screening assays for tyrosine kinase inhibitors: A review.


Journal

Journal of pharmaceutical and biomedical analysis
ISSN: 1873-264X
Titre abrégé: J Pharm Biomed Anal
Pays: England
ID NLM: 8309336

Informations de publication

Date de publication:
20 Jan 2023
Historique:
received: 22 08 2022
revised: 13 11 2022
accepted: 14 11 2022
pubmed: 21 11 2022
medline: 30 11 2022
entrez: 20 11 2022
Statut: ppublish

Résumé

Tyrosine kinases have been intensively investigated as drug targets for several decades, since they regulate many cellular processes including cell growth, differentiation, and proliferation. Indeed, the deregulation of tyrosine kinases has been confirmed to play a vital role in the pathophysiology of many diseases. During the last few years, varieties of techniques have been developed to search for new tyrosine kinase inhibitors for cancer therapy, such as traditional filtration binding assay, scintillation proximity assay and some high-throughput screening methods. In this review, we describe the basic rules, merits and demerits, and application of a number of general and advanced technologies. The purpose of this review is to provide an insight into the numerous assays to achieve the exploration of new tyrosine kinase inhibitors.

Identifiants

pubmed: 36403346
pii: S0731-7085(22)00587-8
doi: 10.1016/j.jpba.2022.115166
pii:
doi:

Substances chimiques

Protein-Tyrosine Kinases EC 2.7.10.1
Protein Kinase Inhibitors 0
Tyrosine 42HK56048U

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

115166

Informations de copyright

Copyright © 2022 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Editor of JPBA Virtual Special Issue, ZJ. J.

Auteurs

Juan Gao (J)

Institute of Pharmaceutical Analysis/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, Guangzhou 510632, China; KU Leuven - University of Leuven, Pharmaceutical Analysis, Department of Pharmaceutical and Pharmacological Sciences, O&N2, PB 923, Herestraat 49, 3000 Leuven, Belgium.

Jingyi Jian (J)

Institute of Pharmaceutical Analysis/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, Guangzhou 510632, China; KU Leuven - University of Leuven, Pharmaceutical Analysis, Department of Pharmaceutical and Pharmacological Sciences, O&N2, PB 923, Herestraat 49, 3000 Leuven, Belgium.

Zhengjin Jiang (Z)

Institute of Pharmaceutical Analysis/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, College of Pharmacy, Jinan University, Guangzhou 510632, China. Electronic address: jzjjackson@hotmail.com.

Ann Van Schepdael (A)

KU Leuven - University of Leuven, Pharmaceutical Analysis, Department of Pharmaceutical and Pharmacological Sciences, O&N2, PB 923, Herestraat 49, 3000 Leuven, Belgium. Electronic address: Ann.VanSchepdael@kuleuven.be.

Articles similaires

Humans Melanoma Skin Neoplasms Antineoplastic Combined Chemotherapy Protocols Randomized Controlled Trials as Topic
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Humans Dyrk Kinases Protein Serine-Threonine Kinases Protein-Tyrosine Kinases Epithelial-Mesenchymal Transition
Humans Induced Pluripotent Stem Cells Schizophrenia Neural Stem Cells DNA Damage

Classifications MeSH